Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study

Cardiovascular Diabetology

Original Investigation

Giuseppa Castellino¹  Dragana Nikolic¹  Angelo Maria Patti¹  Rosaria Vincenza Giglio¹  Manfredi Rizzo²  Giuseppe Montalto³  Giovanni Li Volti⁴  Vincenzo Provenzano⁵  Ali A. Rizvi⁶  Stefano Genovese⁷  Antonio Ceriello⁸  Massimiliano Caprio⁹ 

[1] Biomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy;Biomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy;Division of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, Columbia, SC, USA;Biomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy;Institute of Biomedicine and Molecular Immunology “Alberto Monroy”, National Research Council (CNR), Palermo, Italy;Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy;Department of Internal Medicine, Regional Center for Diabetology, Partinico Hospital, Partinico, Italy;Division of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, Columbia, SC, USA;IRCCS MultiMedica, Milan, Italy;IRCCS MultiMedica, Milan, Italy;Diabetes and Endocrinology, Insititut d’Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Hospital Clínic Barcelona, Barcelona, Spain;Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele Pisana, Rome, Italy;Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, Rome, Italy;

关键词: Liraglutide;    Cardiovascular risk;    Carotid intima-media thickness;    Metabolic syndrome;   

DOI  :  10.1186/s12933-016-0480-8

 received in 2016-09-06, accepted in 2016-11-22,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundLiraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM.MethodsWe performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500–3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter.ResultsThere was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months.ConclusionsLiraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study.Trial Registration ClinicalTrials.gov: NCT01715428.

【 授权许可】

CC BY   
© The Author(s) 2016